Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

39 results about "Amiodarone Hydrochloride" patented technology

The hydrochloride salt of an iodine-rich benzofuran derivative with antiarrhythmic and vasodilatory activities. As a class III antiarrhythmic agent, amiodarone blocks the myocardial calcium, potassium and sodium channels in cardiac tissue, resulting in prolongation of the cardiac action potential and refractory period. In addition, this agent inhibits alpha- and beta-adrenergic receptors, resulting in a reduction in sympathetic stimulation of the heart, a negative chronotropic effect, and a decrease in myocardial oxygen demands. Amiodarone may cause vasodilation by stimulation of the release of nitric oxide and cyclooxygenase-dependent relaxing endothelial factors.

Analysis method for related substances in amiodarone hydrochloride bulk drugs

The invention discloses an analysis method for related substances in amiodarone hydrochloride bulk drugs, and relates to the technical field of chemical drug analysis methods. High performance liquid chromatograph is used carry out analysis according to chromatogram conditions A and B respectively and then in a combined way; the chromatogram conditions A and B include a chromatographic column of Welch Ultimate AQ-C18, a mobile phase A in which the proportion of an acetic acid-ammonium acetate buffer solution to a methanol and acetonitrile mixed solution is 49-51vt% to 51-49vt%, a mobile phase B in which the ratio of methanol to acetonitrile is 30vt% to 40vt%, and the detection wavelength for gradient wash out is 240+ / -2nm; the ratio of methanol to acetonitrile in the methanol and acetonitrile mixed solution is 30vt% to 40vt%; the pH value of the acetic acid-ammonium acetate buffer solution in the chromatogram condition A is 5.95-6.05; and the pH value of the acetic acid-ammonium acetate buffer solution in the chromatogram condition B is 4.85-4.95. Thus, more impurities can be detected, and related substances in amiodarone hydrochloride can monitored rapidly, effectively and accurately.
Owner:合肥拓锐生物科技有限公司

Preparation and application of amiodarone molecular imprinting solid-phase extraction column

The invention relates to preparation of an adsorbing material and application of the adsorbing material to separation and enrichment of medicaments. The invention relates to an amiodarone hydrochloride molecular imprinting polymer, and preparation and application of an amiodarone hydrochloride molecular imprinting solid-phase extraction column. In the molecular imprinting polymer, amiodarone serves as a template; 4-vinyl pyridine is a functional monomer; ethylene glycol dimethacrylate is a crosslinking agent; and chloroform is a porogenic agent. The molecular imprinting polymer is synthesized by a bulk polymerization method; and molecular imprinting polymer particles are filled in the solid-phase extraction column uniformly so as to obtain the amiodarone hydrochloride molecular imprinting solid-phase extraction column. Amiodarone hydrochloride in biological samples is separated, enriched and purified efficiently. Compared with relative techniques such as the past common solvent extraction method, a C18 solid-phase extraction method and the like, the invention has the advantages that: selectivity is high; and the amiodarone hydrochloride molecular imprinting solid-phase extraction column can be reused, has low cost and is expected to become a necessary method for pretreatment of the amiodarone hydrochloride in the biological samples.
Owner:XINJIANG UNIVERSITY

Amiodarone hydrochloride nanosuspension as well as preparation method and application thereof

The invention belongs to the field of medicines, and particularly relates to an amiodarone hydrochloride nanosuspension as well as a preparation method and application thereof. The amiodarone hydrochloride nanosuspension provided by the invention mainly contains amiodarone hydrochloride and a stabilizer, and the amiodarone hydrochloride nanosuspension is prepared from the following components in parts by weight: 1 to 10 parts of amiodarone hydrochloride and 1 to 10 parts of a stabilizer. The nanosuspension with the particle size ranging from 150 nm to 800 nm is provided through two means, and the method comprises the steps that the nanosuspension is ground through a wet method, and the nanosuspension serves as an intermediate product and is further prepared into an oral preparation or an injection preparation for application. The preparation method comprises the following steps: A, dissolving the stabilizer in water, and dispersing the SKLB610 in the solution to prepare a common suspension; and B, adding a common suspension, and carrying out wet grinding to prepare the nano-suspension. Or an anti-solvent is adopted to precipitate the nano-suspension, and the nano-suspension is used as an intermediate product to be further prepared into an oral preparation or an injection preparation for application. The particle size of the nanosuspension can be effectively and intensively controlled to be 150-800 nm, the product uniformity is high, and the particle size is small.
Owner:HUANGHUAI UNIV

Preparation method of amiodarone hydrochloride intermittent

The invention belongs to the field of medicine synthesis, and relates to a preparation method of an amiodarone hydrochloride intermittent. The method is characterized by including the following stepsthat 1, under an alkaline condition, in the presence of a phase transfer catalyst, a compound 1 and a compound 2 are subjected to nucleophilic substitution reaction to obtain a compound 3; 2, under analkaline condition, the compound 3 is hydrolyzed to generate a compound 4; 3, the compound 4 is subjected to intramolecular aldol condensation, decarboxylation and dehydration to obtain a compound 5;4, a compound 6 and thionyl chloride are subjected to heating reaction to obtain a compound 7; 5, under the presence of lewis acid, the compound 5 and the compound 7 are subjected to friede-crafts acylation reaction to obtain a compound 8; 6, under the presence of lewis acid, the compound 8 is subjected to demethylation to generate a compound 9, namely the amiodarone hydrochloride intermittent 2-butyl-3-(4-hydroxybenzoyl)benzofuran. The preparation method of the amiodarone hydrochloride intermittent has the advantages of being short in reaction time, high in product purity and high in yield,and the amiodarone hydrochloride intermittent is suitable for large-scale industrial production.
Owner:BEIJING SHENLANHAI BIO PHARM TECH

Anti-arrhythmic drug fat emulsion injection and preparation method thereof

The invention discloses an anti-arrhythmic drug fat emulsion injection and a preparation method thereof. The anti-arrhythmic drug fat emulsion injection is an amiodarone hydrochloride fat emulsion injection which contains amiodarone hydrochloride and a medicinal excipient acceptable pharmaceutically, wherein the medicinal excipient is prepared from an oil phase, an emulsifier, an osmotic pressure regulator, a stabilizing agent, a pH regulator and water for injection. The anti-arrhythmic drug fat emulsion injection is stable in quality and non-irritant to blood vessels, and the security and compliance of clinical drug application are improved.
Owner:WUHAN CONFORM PHARMA CO LTD

Preparation method of amiodarone hydrochloride key intermediate

The invention discloses a preparation method of an amiodarone hydrochloride key intermediate. The method comprises the following steps: reacting benzofuranone with p-methoxybenzoyl chloride and valeryl chloride, and heating and reacting the product under an acidic condition to obtain the amiodarone hydrochloride key intermediate. According to the method, the key intermediate of amiodarone hydrochloride is prepared through a two-step simple reaction, the reaction condition is mild, byproducts are few, and aftertreatment is easy; due to the fact that aluminum trichloride is not used, no solid waste is generated; and the method has the advantages of simple route operation, high yield and lower cost than the existing route, and is very suitable for industrial production.
Owner:SUZHOU HOMESUN PHARMA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products